Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 634

1.

Mass spectrometry-based proteomics reveals the distinct nature of the skin proteomes of photoaged compared to intrinsically aged skin.

Newton VL, Riba-Garcia I, Griffiths CEM, Rawlings AV, Voegeli R, Unwin RD, Sherratt MJ, Watson REB.

Int J Cosmet Sci. 2019 Jan 20. doi: 10.1111/ics.12513. [Epub ahead of print]

PMID:
30661253
2.

Risankizumab versus ustekinumab for plaque psoriasis: a critical appraisal.

Al-Janabi A, Jabbar-Lopez ZK, Griffiths CEM, Yiu ZZN.

Br J Dermatol. 2019 Jan 11. doi: 10.1111/bjd.17624. [Epub ahead of print]

PMID:
30632140
3.

Persistence and Effectiveness of Non-Biologic Systemic Therapies for Moderate-Severe Psoriasis in Adults: a Systematic Review.

Mason KJ, Williams S, Yiu ZZN, McElhone K, Ashcroft DM, Kleyn CE, Jabbar-Lopez ZK, Owen CM, Reynolds NJ, Smith CH, Wilson N, Warren RB, Griffiths CEM.

Br J Dermatol. 2019 Jan 10. doi: 10.1111/bjd.17625. [Epub ahead of print] Review.

PMID:
30628069
4.

HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.

Dand N, Duckworth M, Baudry D, Russell A, Curtis CJ, Lee SH, Evans I, Mason KJ, Alsharqi A, Becher G, Burden AD, Goodwin RG, McKenna K, Murphy R, Perera GK, Rotarescu R, Wahie S, Wright A, Reynolds NJ, Warren RB, Griffiths CEM, Smith CH, Simpson MA, Barker JN; BADBIR study group, the BSTOP study group and the PSORT consortium.

J Allergy Clin Immunol. 2018 Dec 19. pii: S0091-6749(18)32780-5. doi: 10.1016/j.jaci.2018.11.038. [Epub ahead of print]

PMID:
30578879
5.

Selective proteolysis by matrix metalloproteinases of photo-oxidised dermal extracellular matrix proteins.

Hibbert SA, Watson REB, Griffiths CEM, Gibbs NK, Sherratt MJ.

Cell Signal. 2019 Feb;54:191-199. doi: 10.1016/j.cellsig.2018.11.024. Epub 2018 Dec 3.

6.

Burden of suicide presented as one of the leading causes of death: uncover facts or misrepresent statistics?

Gjertsen F, Bruzzone S, Griffiths CE.

J Glob Health. 2019 Jun;9(1):010401. doi: 10.7189/jogh.09.010401.

7.

Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy.

Yiu ZZN, Sorbe C, Lunt M, Rustenbach SJ, Kühl L, Augustin M, Mason KJ, Ashcroft DM, Griffiths CEM, Warren RB; BADBIR Study Group.

Br J Dermatol. 2018 Nov 15. doi: 10.1111/bjd.17421. [Epub ahead of print]

PMID:
30430546
8.

Aging in Skin of Color: Disruption to Elastic Fiber Organization Is Detrimental to Skin's Biomechanical Function.

Langton AK, Alessi S, Hann M, Chien AL, Kang S, Griffiths CEM, Watson REB.

J Invest Dermatol. 2018 Nov 4. pii: S0022-202X(18)32790-8. doi: 10.1016/j.jid.2018.10.026. [Epub ahead of print]

PMID:
30404021
9.

Aged human skin accumulates mast cells with altered functionality that localize to macrophages and vasoactive intestinal peptide-positive nerve fibres.

Pilkington SM, Barron MJ, Watson REB, Griffiths CEM, Bulfone-Paus S.

Br J Dermatol. 2018 Oct 6. doi: 10.1111/bjd.17268. [Epub ahead of print]

PMID:
30291626
10.

A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial.

Cornelius V, Wilson R, Cro S, Barker J, Burden D, Griffiths CEM, Lachmann H, McAteer H, Reynolds N, Pink A, Warren RB, Capon F, Smith C.

Trials. 2018 Aug 29;19(1):465. doi: 10.1186/s13063-018-2841-y.

11.

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study.

Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, Reynolds NJ, Stocken D, Emsley R, Griffiths CEM, Smith C; PSORT Consortium and on behalf of the BADBIR Study Group.

Br J Dermatol. 2018 Aug 28. doi: 10.1111/bjd.16776. [Epub ahead of print]

PMID:
30155885
12.

Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study.

Wilkinson N, Tsakok T, Dand N, Bloem K, Duckworth M, Baudry D, Pushpa-Rajah A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C; BSTOP study group; PSORT consortium.

J Invest Dermatol. 2019 Jan;139(1):115-123. doi: 10.1016/j.jid.2018.07.028. Epub 2018 Aug 18.

13.

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.

Griffiths CEM, Papp KA, Kimball AB, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.

J Drugs Dermatol. 2018 Aug 1;17(8):826-832.

PMID:
30124721
14.

Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.

Davison NJ, Thompson AJ, Turner AJ, Longworth L, McElhone K, Griffiths CEM, Payne K; BADBIR Study Group.

Value Health. 2018 Aug;21(8):1010-1018. doi: 10.1016/j.jval.2017.10.024. Epub 2017 Dec 26.

PMID:
30098665
15.

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group.

Br J Dermatol. 2018 Aug 2. doi: 10.1111/bjd.17036. [Epub ahead of print]

PMID:
30070708
16.

Clinical and genetic differences between pustular psoriasis subtypes.

Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, Cooper HL, Irvine AD, Oon HH, Kingo K, Köks S, Mrowietz U, Puig L, Reynolds N, Tan ES, Tanew A, Torz K, Trattner H, Valentine M, Wahie S, Warren RB, Wright A, Bata-Csörgő Z, Szell M, Griffiths CEM, Burden AD, Choon SE, Smith CH, Barker JN, Navarini AA, Capon F.

J Allergy Clin Immunol. 2018 Jul 21. pii: S0091-6749(18)31039-X. doi: 10.1016/j.jaci.2018.06.038. [Epub ahead of print]

17.

A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis.

Foulkes AC, Watson DS, Carr DF, Kenny JG, Slidel T, Parslew R, Pirmohamed M; PSORT Consortium, Anders S, Reynolds NJ, Griffiths CEM, Warren RB, Barnes MR.

J Invest Dermatol. 2019 Jan;139(1):100-107. doi: 10.1016/j.jid.2018.04.041. Epub 2018 Jul 17.

PMID:
30030151
18.

Psychiatric morbidity and suicidal behaviour in psoriasis: a primary care cohort study.

Parisi R, Webb RT, Kleyn CE, Carr MJ, Kapur N, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2019 Jan;180(1):108-115. doi: 10.1111/bjd.17004. Epub 2018 Oct 10.

PMID:
30007069
19.

Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.

Paul C, Griffiths CEM, van de Kerkhof PCM, Puig L, Dutronc Y, Henneges C, Dossenbach M, Hollister K, Reich K.

J Am Acad Dermatol. 2019 Jan;80(1):70-79.e3. doi: 10.1016/j.jaad.2018.06.039. Epub 2018 Jun 30.

PMID:
29969700
20.

Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study.

Griffiths CE, Stein Gold L, Cambazard F, Kalb RE, Lowson D, Møller A, Paul C.

Eur J Dermatol. 2018 Jun 1;28(3):356-363. doi: 10.1684/ejd.2018.3302.

PMID:
29952297

Supplemental Content

Loading ...
Support Center